2010Journal of Clinical Pulmonary MedicineRequires access

Clinical investigation on levofloxacin and azithromycin in the treatment of community-acquired pneumonia

Bo Zhang

Open publisher page 0 citations

Abstract

Objective To evaluate the efficacy and safety of levofloxacin and azithromycin in the treatment of community-acquired pneumonia (CAP).Methods Fifty-six patients with CAP were randomly divided into two groups:① treatment group:the patients were treated with levofloxacin and azithromycin. ② control group:the patients were treated with levofloxacin alone. Both groups were treated for 7~14 days. Efficacy and safety of levofloxacin and azithromycin in the treatment were observed.Results The overall efficacy was 96.42% for the treatment group and 82.14% for the control group. The results showed that there were significant differences between the two groups (P0.05);The rates of the side effects were 14.29% and 21.43%,respectively. There were no significant differences between the two groups (P0.05).Conclusion Levofloxacin and azithromycin in the treatment of community-acquired pneumonia (CAP) can improve efficacy,shorten the course of disease and are well tolerated.

About this research paper

What this paper is about

Objective To evaluate the efficacy and safety of levofloxacin and azithromycin in the treatment of community-acquired pneumonia (CAP).Methods Fifty-six patients with CAP were randomly divided into two groups:① treatment group:the patients were treated with levofloxacin and azithromycin. ② control group:the patients were treated with levofloxacin alone. Both groups were treated for 7~14 days. Efficacy and safety of levofloxacin and azithromycin in the treatment were observed.Results The overall efficacy was 96.42% for the treatment group and 82.14% for the control group. The results showed that there were significant differences between the two groups (P0.05);The rates of the side effects were 14.29% and 21.43%,respectively. There were no significant differences between the two groups (P0.05).Conclusion Levofloxacin and azithromycin in the treatment of community-acquired pneumonia (CAP) can improve efficacy,shorten the course of disease and are well tolerated.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To evaluate the efficacy and safety of levofloxacin and azithromycin in the treatment of community-acquired pneumonia (CAP).Methods Fifty-six patients with CAP were randomly divided into two groups:① treatment group:the patients were treated with levofloxacin and azithromycin. ② control group:the patients were treated with levofloxacin alone. Both groups were treated for 7~14 days. Efficacy and safety of levofloxacin and azithromycin in the treatment were observed.Results The overall efficacy was 96.42% for the treatment group and 82.14% for the control group. The results showed that there were significant differences between the two groups (P0.05);The rates of the side effects were 14.29% and 21.43%,respectively. There were no significant differences between the two groups (P0.05).Conclusion Levofloxacin and azithromycin in the treatment of community-acquired pneumonia (CAP) can improve efficacy,shorten the course of disease and are well tolerated.

Key concepts: Levofloxacin, Azithromycin, Medicine, Community-acquired pneumonia, Pneumonia, Internal medicine, Clinical efficacy, Treatment and control groups

Related papers

Back to paper searchBrowse research topicsOriginal source
Clinical investigation on levofloxacin and azithromycin in the treatment of community-acquired pneumonia — Research Paper | ScholarLens